デング熱患者における EYU688 の有効性、安全性、薬物動態を評価する研究
デング熱患者におけるEYU688の有効性、安全性および薬物動態を評価するための、無作為化、参加者および研究者盲検、プラセボ対照並行グループ研究
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
調査の概要
状態
状態
条件
条件
詳細な説明
This is a randomized, participant- and investigator- blinded, placebo-controlled study to investigate the efficacy and safety of EYU688 administered orally in patients with dengue fever.
Due to the different PK sampling schedules applied, the study consists of two cohorts run in parallel (intensive PK [cohort 1] and sparse PK sampling [cohort 2]).
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Novartis Pharmaceuticals
- 電話番号:+41613241111
- メール:novartis.email@novartis.com
研究連絡先のバックアップ
- 名前:Novartis Pharmaceuticals
研究場所
-
-
Karnataka
-
Belagavi、Karnataka、インド、590010
- 募集
- Novartis Investigative Site
-
-
Maharashtra
-
Mumbai、Maharashtra、インド、400008
- 引きこもった
- Novartis Investigative Site
-
Pune、Maharashtra、インド、411013
- 募集
- Novartis Investigative Site
-
-
Rajasthan
-
Jaipur、Rajasthan、インド、302017
- 募集
- Novartis Investigative Site
-
-
Tamil Nadu
-
Chennai、Tamil Nadu、インド、600113
- 募集
- Novartis Investigative Site
-
-
-
-
Atlántico
-
Barranquilla、Atlántico、コロンビア、080012
- 募集
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga、Santander Department、コロンビア、681017
- 募集
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali、Valle del Cauca Department、コロンビア、760032
- 募集
- Novartis Investigative Site
-
-
-
-
-
Singapore、シンガポール、169608
- 募集
- Novartis Investigative Site
-
-
Singapore
-
Singapore、Singapore、シンガポール、308433
- 募集
- Novartis Investigative Site
-
-
-
-
Amazonas
-
Manaus、Amazonas、ブラジル、69040-000
- 募集
- Novartis Investigative Site
-
-
Federal District
-
Brasília、Federal District、ブラジル、71635-580
- 募集
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、ブラジル、90560-032
- 募集
- Novartis Investigative Site
-
-
Rio de Janeiro
-
Rio de Janeiro、Rio de Janeiro、ブラジル、21040-360
- 募集
- Novartis Investigative Site
-
-
São Paulo
-
Sorocaba、São Paulo、ブラジル、18040-425
- 募集
- Novartis Investigative Site
-
São Caetano do Sul、São Paulo、ブラジル、09521-160
- 募集
- Novartis Investigative Site
-
São José do Rio Preto、São Paulo、ブラジル、15090 000
- 募集
- Novartis Investigative Site
-
-
-
-
-
Haiphong、ベトナム、180000
- 募集
- Novartis Investigative Site
-
Hanoi、ベトナム、100000
- 募集
- Novartis Investigative Site
-
Ho Chi Minh City、ベトナム、700000
- 募集
- Novartis Investigative Site
-
-
-
-
-
Kuala Selangor、マレーシア、68000
- 募集
- Novartis Investigative Site
-
-
Pahang
-
Kuantan、Pahang、マレーシア、25200
- 募集
- Novartis Investigative Site
-
-
Perak
-
Ipoh、Perak、マレーシア、30450
- 募集
- Novartis Investigative Site
-
-
Pulau Pinang
-
Seberang Jaya、Pulau Pinang、マレーシア、13700
- 募集
- Novartis Investigative Site
-
-
Sarawak
-
Miri、Sarawak、マレーシア、98000
- 募集
- Novartis Investigative Site
-
-
-
-
-
Oaxaca City、メキシコ、68020
- 募集
- Novartis Investigative Site
-
Veracruz、メキシコ、91855
- 募集
- Novartis Investigative Site
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female, 18 - 60 years old (inclusive).
- History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection:
- Nausea or vomiting.
- Presence of rash, aches or pains including headache, muscle or joint pain.
- Onset of fever ≤ 48 hours prior to treatment start.
- Positive test on dengue fever.
Exclusion Criteria:
-
Participants with any of abnormalities of clinical laboratory parameters.
-
Usage of any anticoagulant drugs.
-
Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.
-
Pregnant or nursing (lactating) women.
-
Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.
-
Participants with any of the following abnormalities of clinical laboratory parameters at screening:
- Hemoglobin <12.0 g/dL in males; <11.0 g/dL in females
- Hematocrit >52 % in males; >46 % in females
- Absolute neutrophil count <1500/μL
- Platelet count <80,000/mm3
- Creatinine >165 μmol/L in males; >130 μmol/L in females
- Serum creatine kinase > 600 U/L
- ALT, AST levels more than 3 X upper limit of normal (ULN)
- Total bilirubin >24 μmol/L
-
Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening.
-
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.
-
History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening:
- QTcF > 450 msec (males)
- QTcF > 460 msec (females)
Other protocol-defined inclusion/exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
Matching placebo |
Matching placebo administered orally as capsules |
|
実験的:EYU688
EYU688 administered by oral route |
EYU688 administered by oral route |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Viremia reduction (viral load reduction (VLR) on log scale) at 48 hours post treatment start
時間枠:From predose to 48 hours post treatment start
|
Efficacy assessment of EYU688. It will allow to quantify the viremia reduction at 48 hours post treatment start from baseline. |
From predose to 48 hours post treatment start
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time from fever onset to start of the first 48 hours period during which the oral temperature remained below 37.5℃
時間枠:From fever onset to Day 15
|
Efficacy assessment of EYU688. It will allow to assess the time needed between fever onset and defervescence. |
From fever onset to Day 15
|
|
Time from fever onset to the first of two consecutive negative viremia by PCR
時間枠:From fever onset to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15 |
From fever onset to Day 15
|
|
Area under the log-transformed viremia curve (AUC) from the first dose to Day 15
時間枠:From fever onset to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day 15 |
From fever onset to Day 15
|
|
Changes of viral load over time
時間枠:From baseline to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15 |
From baseline to Day 15
|
|
Incidence and severity of Adverse Events (AEs)
時間枠:From inclusion to Day 15
|
Incidence and severity of AEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs. |
From inclusion to Day 15
|
|
Incidence and severity of Serious Adverse Events (SAEs)
時間枠:From inclusion to Day 35
|
Incidence and severity of SAEs by treatment group |
From inclusion to Day 35
|
|
Change of white blood cell count over time from baseline
時間枠:From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of platelet count over time
時間枠:From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of hematocrit level and percentage increase from baseline over time
時間枠:From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of AST, ALT levels over time
時間枠:From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
No warning signs by day 7 of fever onset
時間枠:From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Diagnosis of severe dengue fever
時間枠:From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Diagnosis of dengue hemorrhagic fever (DHF)
時間枠:From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Plasma leakage
時間枠:From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Requiring fluid infusion
時間枠:From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Time from fever onset to clinical recovery
時間枠:From fever onset to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From fever onset to Day 15
|
|
PK parameter (Cmax)
時間枠:From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK parameter (Tmax)
時間枠:From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK parameter (partial AUCs)
時間枠:From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK concentrations following multiple doses
時間枠:From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CEYU688A12201
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。